| Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus (NCT03792347) | Hecheng Li M.D., Ph.D | 2019-01-21 |
| Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma (NCT03387904) | The First Affiliated Hospital of Zhengzhou University | 2019-01-13 |
| Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features (NCT07181850) | Nanjing Medical University | 2019-01-01 |
| Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (NCT03748134) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-12-24 |
| Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence (NCT03322267) | National Taiwan University Hospital | 2018-10-27 |
| Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial (NCT03713749) | Chang Gung Memorial Hospital | 2018-10-22 |
| Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma (NCT03790553) | Fudan University | 2018-10-15 |
| Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma (NCT03600831) | Huai'an First People's Hospital | 2018-08-20 |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer (NCT03603756) | Chinese Academy of Medical Sciences | 2018-07-31 |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT03817567) | Sinocelltech Ltd. | 2018-07-17 |
| Changhai Multimodal Esophageal Cancer Cohort (NCT06410677) | Wangluowei | 2018-06-13 |
| Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer (NCT03474341) | UMC Utrecht | 2018-04-09 |
| Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer (NCT03377400) | Samsung Medical Center | 2017-12-14 |
| Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin (NCT03273647) | Fudan University | 2017-12-01 |
| Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma (NCT03660449) | Sun Yat-sen University | 2017-10-01 |
| Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (NCT03251417) | Peking University | 2017-09-10 |
| Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification (NCT03888092) | Sunshine Lake Pharma Co., Ltd. | 2017-08-18 |
| NCI UNC Project ESCC (NCT03206125) | National Cancer Institute (NCI) | 2017-08-01 |
| HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi (NCT03160209) | UNC Lineberger Comprehensive Cancer Center | 2017-07-26 |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System (NCT03185988) | Shen Lin | 2017-07-01 |
| Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma (NCT03278626) | NYU Langone Health | 2017-06-27 |
| Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer (NCT03187314) | Hangzhou Cancer Hospital | 2017-06-14 |
| Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment (NCT03116152) | Innovent Biologics (Suzhou) Co. Ltd. | 2017-05-10 |
| Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (NCT03797625) | Fudan University | 2017-05-04 |
| Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (NCT03224221) | The First Affiliated Hospital of Anhui Medical University | 2017-03-23 |
| Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC (NCT03623737) | National Taiwan University Hospital | 2017-03-01 |
| Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) (NCT02844075) | Yonsei University | 2017-01-01 |
| SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma (NCT04115618) | Fudan University | 2017-01-01 |
| Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT02964455) | Sun Yat-sen University | 2016-11-01 |
| Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma (NCT02976909) | Yuhong Li | 2016-10-01 |
| S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma (NCT02913066) | Mianyang Central Hospital | 2016-09-01 |
| Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma (NCT02916511) | Fudan University | 2016-09-01 |
| Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease (NCT02890979) | OHSU Knight Cancer Institute | 2016-08-03 |
| Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (NCT02976896) | Yuhong Li | 2016-08-01 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma (NCT02677597) | Fudan University | 2016-01-01 |
| Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma (NCT02645864) | Peking University | 2016-01-01 |
| Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) (NCT02649361) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-01-01 |
| Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas (NCT02665702) | Fudan University | 2016-01-01 |
| Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus (NCT02586753) | Mianyang Central Hospital | 2015-12-01 |
| A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC (NCT02647125) | Fudan University | 2015-09-01 |
| CIK in Treating Patients With Esophageal Cancer (NCT02490735) | The First People's Hospital of Changzhou | 2015-08-01 |
| Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) (NCT02465736) | Sun Yat-sen University | 2015-07-01 |
| Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. (NCT02606916) | Sun Yat-sen University | 2015-07-01 |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma (NCT02272699) | Peking University | 2014-11-01 |
| A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya (NCT00901173) | National Cancer Institute (NCI) | 2014-02-10 |
| Esophageal Cytology With FISH in Detecting Esophageal Cancer (NCT02100189) | OHSU Knight Cancer Institute | 2014-02-01 |
| Proton Beam Therapy to Treat Esophageal Cancer (NCT02023541) | Washington University School of Medicine | 2014-01-01 |
| The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma (NCT06241066) | Tianjin Medical University Cancer Institute and Hospital | 2014-01-01 |
| The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers (NCT02435602) | Maria Sklodowska-Curie National Research Institute of Oncology | 2013-12-01 |
| Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy (NCT01973725) | Yuhong Li | 2013-10-01 |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) (NCT01822613) | Novartis Pharmaceuticals | 2013-07-26 |
| Oral Rigosertib for Squamous Cell Carcinoma (NCT01807546) | Traws Pharma, Inc. | 2013-03-01 |
| Study of S-1 in Combination With Radiotherapy in Esophageal Cancer (NCT01831531) | Fudan University | 2013-03-01 |
| Role of Esophagectomy in Complete Responders to CCRT (NCT01740375) | Asan Medical Center | 2012-11-01 |
| A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer (NCT01598077) | Novartis Pharmaceuticals | 2012-07-01 |
| A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus (NCT01608022) | Yonsei University | 2012-07-01 |
| A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma (NCT01591135) | Fudan University | 2012-04-01 |
| Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer (NCT01551589) | Chengya Chou | 2012-03-01 |
| Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer (NCT04522687) | Shanghai Cancer Hospital, China | 2012-01-01 |
| Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC) (NCT01688908) | Peking University | 2012-01-01 |
| Genome-wide Association Study (NCT01498757) | Samsung Medical Center | 2012-01-01 |
| S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study (NCT01854749) | Fudan University | 2011-11-01 |
| A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer (NCT01391572) | Fudan University | 2011-04-01 |
| Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 (NCT01398449) | Fudan University | 2011-04-01 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (NCT01258192) | Zhejiang Cancer Hospital | 2011-01-01 |
| Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy (NCT01402180) | Fudan University | 2010-12-01 |
| Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia (NCT02047305) | Covidien, GI Solutions | 2009-01-01 |
| Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years (NCT05604950) | Yongtao Han | 2009-01-01 |
| Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer (NCT01605305) | Fudan University | 2008-09-01 |
| Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma (NCT06490003) | City of Hope Medical Center | 2004-06-01 |
| Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma (NCT06241079) | Tianjin Medical University Cancer Institute and Hospital | 2003-03-31 |
| Precisely Estimation of the Prognostic Value of Lymph Node in ESCC (NCT04764240) | Shanghai Cancer Hospital, China | 2003-01-01 |
| Endoscopic Screening on Esophageal Cancer (NCT02094105) | Chinese Academy of Medical Sciences | 1999-11-01 |